Overview and Clinical Classification Cenmox represents a novel formulation in the antimicrobial space, combining amoxicillin with a targeted beta-lactamase inhibitor complex. Developed primarily for respiratory and genitourinary tract infections where resistance patterns have complicated standard therapy, this product emerged from a specific clinical need we kept encountering in our practice around 2018. The formulation contains amoxicillin trihydrate 875mg paired with clavulanate potassium 125mg in a controlled-release matrix. What distinguishes Cenmox from standard amoxicillin-clavulanate combinations is the addition of a proprietary absorption enhancer that modifies gastric transit time.
